KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Capital Employed (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Return on Capital Employed readings, the most recent being 52.8% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 1295.0% to 52.8% in Q4 2025 year-over-year; TTM through Dec 2025 was 52.8%, a 1295.0% decrease, with the full-year FY2025 number at 57.93%, down 13245.0% from a year prior.
  • Return on Capital Employed hit 52.8% in Q4 2025 for Esperion Therapeutics, down from 844.13% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 844.13% in Q3 2025 to a low of 271.36% in Q4 2023.
  • Median Return on Capital Employed over the past 5 years was 85.47% (2022), compared with a mean of 34.63%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -17592bps in 2023 and later soared 83430bps in 2025.
  • Esperion Therapeutics' Return on Capital Employed stood at 98.55% in 2021, then grew by 3bps to 95.44% in 2022, then tumbled by -184bps to 271.36% in 2023, then surged by 124bps to 65.75% in 2024, then dropped by -20bps to 52.8% in 2025.
  • The last three reported values for Return on Capital Employed were 52.8% (Q4 2025), 844.13% (Q3 2025), and 96.43% (Q2 2025) per Business Quant data.